NCT01802866View on ClinicalTrials.gov

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions
Geographic Atrophy
Interventions
DRUG

ACU-4429

Take orally once daily for 24 months

DRUG

Placebo

Take orally once daily for 24 months

Trial Locations (1)

Unknown

Phoenix

Sponsors

Lead Sponsor

Kubota Vision Inc.
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Kubota Vision Inc.

INDUSTRY